Mitoxantrone

Generic Name
Mitoxantrone
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C22H28N4O6
CAS Number
65271-80-9
Unique Ingredient Identifier
BZ114NVM5P
Background

An anthracenedione-derived antineoplastic agent.

Indication

For the treatment of secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis

Associated Conditions
Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Promyelocytic Leukemia, Hodgkin's Lymphoma, Metastatic Breast Cancer, Non-Hodgkin's Lymphoma (NHL), Progressive Relapsing Multiple Sclerosis, Relapsed Leukemia, Relapsed Lymphomas, Relapsing Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS), Hormone refractory, advanced Prostate cancer, Relapsed Hepatocellular carcinoma
Associated Therapies
Autologous hematopoietic stem cell transplant

Continuous Infusion Chemotherapy (CI-CLAM) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms

First Posted Date
2019-12-12
Last Posted Date
2023-12-28
Lead Sponsor
University of Washington
Target Recruit Count
13
Registration Number
NCT04196010
Locations
🇺🇸

Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Medium Dose of Cytarabine and Mitoxantrone

First Posted Date
2019-07-18
Last Posted Date
2019-07-18
Lead Sponsor
Shenzhen People's Hospital
Target Recruit Count
250
Registration Number
NCT04024241
Locations
🇨🇳

Shenzhen, Shenzhen, Guangdong, China

Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage

First Posted Date
2019-04-24
Last Posted Date
2022-10-20
Lead Sponsor
Delta-Fly Pharma, Inc.
Target Recruit Count
450
Registration Number
NCT03926624
Locations
🇺🇸

University of California, Irvine, California, United States

🇺🇸

Decatur Memorial Hospital-Cancer Care Specialists of Central IL, Decatur, Illinois, United States

🇺🇸

The University of Mississippi Medical Center, Jackson, Mississippi, United States

and more 36 locations

Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia

First Posted Date
2019-03-04
Last Posted Date
2024-05-16
Lead Sponsor
Sanofi
Target Recruit Count
67
Registration Number
NCT03860844
Locations
🇺🇸

Children's Medical Center of Dallas-Site Number:8400002, Dallas, Texas, United States

🇲🇽

Investigational Site Number :4840001, Monterrey, Nuevo León, Mexico

🇧🇷

Investigational Site Number :0760007, Porto Alegre, Rio Grande Do Sul, Brazil

and more 38 locations

Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I Trial

First Posted Date
2018-11-08
Last Posted Date
2019-06-12
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
2
Registration Number
NCT03735446
Locations
🇺🇸

Dana Farber Cancer Institute, Boston, Massachusetts, United States

A Study of DSP-2033 (Alvocidib) in Patients With Acute Myeloid Leukemia

First Posted Date
2018-06-20
Last Posted Date
2022-04-12
Lead Sponsor
Sumitomo Pharma Co., Ltd.
Target Recruit Count
10
Registration Number
NCT03563560
Locations
🇯🇵

Fukui University Hospital, Yoshida-gun, Fukui, Japan

🇯🇵

Chugoku Central Hospital, Fukuyama, Hiroshima, Japan

🇯🇵

Hokkaido University Hospital, Sapporo, Hokkaido, Japan

and more 8 locations

Lintuzumab-Ac225 in Combination with Cladribine + Cytarabine + Filgastrim + Mitoxantrone (CLAG-M) for Relapsed/Refractory Acute Myeloid Leukemia

First Posted Date
2018-02-22
Last Posted Date
2024-10-07
Lead Sponsor
Medical College of Wisconsin
Target Recruit Count
26
Registration Number
NCT03441048
Locations
🇺🇸

Froedtert Hospital and the Medical College of Wisconsin, Milwuakee, Wisconsin, United States

Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML

First Posted Date
2017-08-15
Last Posted Date
2021-04-30
Lead Sponsor
Arog Pharmaceuticals, Inc.
Target Recruit Count
322
Registration Number
NCT03250338
Locations
🇺🇸

Kansas University, Kansas City, Kansas, United States

🇺🇸

Roswell Park Cancer Institute, Buffalo, New York, United States

🇨🇦

University of Alberta, Edmonton, Alberta, Canada

and more 59 locations

A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia

First Posted Date
2017-05-23
Last Posted Date
2024-05-29
Lead Sponsor
St. Jude Children's Research Hospital
Target Recruit Count
206
Registration Number
NCT03164057
Locations
🇺🇸

Rady Children's Hospital and Health Center, San Diego, California, United States

🇺🇸

Children's Hospital of Central California, Madera, California, United States

🇺🇸

Children's Hospital of Orange County, Orange, California, United States

and more 7 locations
© Copyright 2024. All Rights Reserved by MedPath